Rein Therapeutics Inc. (RNTX) Earnings History
Annual and quarterly earnings data from 2020 to 2024
Loading earnings history...
RNTX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
RNTX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export RNTX earnings history in CSV or JSON format
Free sign-in required to download data
Rein Therapeutics Inc. (RNTX) Earnings Overview
As of May 8, 2026, Rein Therapeutics Inc. (RNTX) reported trailing twelve-month net income of -$59M, reflecting -2.6% year-over-year growth. The company earned $-2.23 per diluted share over the past four quarters.
Looking at the long-term picture, RNTX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$15,732 in fiscal 2023.
Rein Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ATXI (-$4M net income), NKTR (-$164M net income, -297.1% margin), INVA ($504M net income, 63.8% margin), RNTX has comparable earnings metrics. Compare RNTX vs ATXI →
RNTX Earnings vs Peers
Earnings metrics vs comparable public companies
RNTX Historical Earnings Data (2020–2024)
5 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$63M | -399614.0% | -$65M | $-3.51 | - | - |
| 2023 | $-15,732 | +42.4% | $-16,276 | $-3.42 | - | - |
| 2022 | $-27,329 | -4.5% | $-27,647 | $-6.02 | - | - |
| 2021 | $-26,164 | -23.7% | $-26,605 | $-5.89 | - | - |
| 2020 | $-21,157 | - | $-20,496 | $-0.00 | - | - |
See RNTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RNTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RNTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRNTX — Frequently Asked Questions
Quick answers to the most common questions about buying RNTX stock.
Is RNTX growing earnings?
RNTX EPS of $-2.23 reflects slowing growth at -2.6%, below the 5-year CAGR of N/A. TTM net income is $-59M. Expansion rate has moderated.
What are RNTX's profit margins?
Rein Therapeutics Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are RNTX's earnings?
RNTX earnings data spans 2020-2024. The current earnings trend is -2.6% YoY. Historical data enables comparison across business cycles.